Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$5.07 USD

5.07
229,932

+0.05 (1.00%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $5.05 -0.02 (-0.39%) 7:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines

by Zacks Equity Research

Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.

Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.

Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

by Zacks Equity Research

Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.

Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat

by Zacks Equity Research

Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.

Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls

by Zacks Equity Research

Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.

Ekta Bagri headshot

5 Biotech Stocks to Consider for Your Portfolio in 2024

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?

by Zacks Equity Research

Puma Biotech (PBYI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

by Zacks Equity Research

Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.

Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

by Zacks Equity Research

Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.

PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PBYI vs. AMGN: Which Stock Is the Better Value Option?

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

by Zacks Equity Research

Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.

Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted

by Zacks Equity Research

Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.

JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program

by Zacks Equity Research

JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

by Zacks Equity Research

REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.

Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury

by Zacks Equity Research

Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.

Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss

by Zacks Equity Research

Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

by Zacks Equity Research

Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.

Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC

by Zacks Equity Research

Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.

Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B

by Zacks Equity Research

Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.

Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales

by Zacks Equity Research

Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.

Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates

by Zacks Equity Research

Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.

Vaishali Doshi headshot

4 Top-Performing Liquid Stocks to Strengthen Your Portfolio

by Vaishali Doshi

Here are four top-performing liquid stocks, Netflix (NFLX), Oceaneering International (OII), Puma Biotechnology (PBYI) and GigaCloud (GCT) which investors can add to their portfolio to boost returns.